Advertisement

Topics

MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System

10:13 EDT 14 May 2019 | Businesswire

MC10, Inc.

MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to explore a range of outcome measures in patients with multiple sclerosis (MS) using the BioStamp nPoint® system.

This innovative, patient-focused endeavor aims to explore the use of data from the nPoint® System in order to provide unique insights into MS clinical studies. “We are excited to work with a world leader in CNS therapies and look forward to exploring novel data and metrics that help to advance clinical development” commented Dr Arthur Combs, Chief Medical Officer of MC10.

The 510(k) cleared BioStamp nPoint System was developed for use in clinical trials and other applications for the continuous collection of physiological data and is optimized for both in-home and in-clinic use. The system reports vital signs, activity and postural classifications and a suite of sleep metrics. The BioStamp nPoint System is in use today by numerous pharmaceutical companies and in academic research across several therapeutic areas.

“We are excited to explore the BioStamp nPoint System’s ability to unobtrusively collect clinically relevant data continuously from subjects in more natural settings. This technology has the potential to improve the quality of data we collect and at the same time reduce the burden on study participants,” commented Dr. Michael Gold, Vice President, Development Neurosciences, of AbbVie.

About MC10
MC10 is a privately held company, backed by a strong syndicate of financial and strategic investors, that is improving human health through digital healthcare solutions. The company combines its proprietary ultra-thin, flexible body-worn sensors with advanced analytics to unlock health insights from physiological data. MC10 is headquartered in Lexington, MA. Visit MC10 online at https://www.mc10inc.com.

MC10®, BioStamp nPoint®, and the MC10 logo are registered marks owned by MC10, Inc.

MC10, Inc.
Katie Nolan
knolan@mc10inc.com

NEXT ARTICLE

More From BioPortfolio on "MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...